Limits...
Characteristics of human amniotic fluid mesenchymal stem cells and their tropism to human ovarian cancer.

Li L, Wang D, Zhou J, Cheng Y, Liang T, Zhang G - PLoS ONE (2015)

Bottom Line: We successfully isolated the AFMSCs from thirteen of twenty amniotic fluid samples.RT-PCR results showed that the AFMSCs expressed stem cell marker OCT4.Meanwhile, the research emphasis in the future can also put in targeting therapy of ovarian cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Genecology and Obstetrics, Harbin Medical University, Harbin, Heilongjiang, China.

ABSTRACT
The mesenchymal stem cells (MSCs) derived from amniotic fluid (AF) have become an attractive stem cells source for cell-based therapy because they can be harvested at low cost and avoid ethical disputes. In human research, stem cells derived from AF gradually became a hot research direction for disease treatment, specifically for their plasticity, their reduced immunogenicity and their tumor tropism regardless of the tumor size, location and source. Our work aimed to obtain and characterize human amniotic fluid mesenchymal stem cells (AFMSCs) and detect their ovarian cancer tropsim in nude mice model. Ten milliliters of twenty independent amniotic fluid samples were collected from 16-20 week pregnant women who underwent amniocentesis for fetal genetic determination in routine prenatal diagnosis in the first affiliated hospital of Harbin medical university. We successfully isolated the AFMSCs from thirteen of twenty amniotic fluid samples. AFMSCs presented a fibroblastic-like morphology during the culture. Flow cytometry analyses showed that the cells were positive for specific stem cell markers CD73,CD90, CD105, CD166 and HLA-ABC (MHC class I), but negative for CD 45,CD40, CD34, CD14 and HLA-DR (MHC class II). RT-PCR results showed that the AFMSCs expressed stem cell marker OCT4. AFMSCs could differentiate into bone cells, fat cells and chondrocytes under certain conditions. AFMSCs had the high motility to migrate to ovarian cancer site but didn't have the tumorigenicity. This study enhances the possibility of AFMSCs as drug carrier in human cell-based therapy. Meanwhile, the research emphasis in the future can also put in targeting therapy of ovarian cancer.

No MeSH data available.


Related in: MedlinePlus

Detecting the tropism of AFMSCs to human ovarian cancer by immunochemistry.(A) The expression of CD90 in liver, spleen, lung, kidney and tumor in both groups. (B) Laser scanning confocal detected the expression of the red fluorescence in liver, spleen, lung, kidney and tumor in both groups.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4400015&req=5

pone.0123350.g007: Detecting the tropism of AFMSCs to human ovarian cancer by immunochemistry.(A) The expression of CD90 in liver, spleen, lung, kidney and tumor in both groups. (B) Laser scanning confocal detected the expression of the red fluorescence in liver, spleen, lung, kidney and tumor in both groups.

Mentions: CD90 immunohistochemical results show that the CD90 mainly expressed in the tumor after the mice were injected with AFMSCs, and only a few AFMSCs were observed in the liver and spleen. The control group showed negative CD90 expression in the tumor and other tissues(Fig 7A) From the laser scanning confocal results we could see the red fluorescent labeled amniotic fluid mesenchymal stem cells in the experimental group with mainly gathered in the tumor site, and small number of stem cells appeared in the liver and spleen. The negative control group showed no red fluorescence(Fig 7B). The results might prompt that the AFMSCs had the tropism to ovarian cancer but not the normal tissue. The exhilarated discoveries also indicated the possibility of ovarian cancer cell-based targeted therapy.


Characteristics of human amniotic fluid mesenchymal stem cells and their tropism to human ovarian cancer.

Li L, Wang D, Zhou J, Cheng Y, Liang T, Zhang G - PLoS ONE (2015)

Detecting the tropism of AFMSCs to human ovarian cancer by immunochemistry.(A) The expression of CD90 in liver, spleen, lung, kidney and tumor in both groups. (B) Laser scanning confocal detected the expression of the red fluorescence in liver, spleen, lung, kidney and tumor in both groups.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4400015&req=5

pone.0123350.g007: Detecting the tropism of AFMSCs to human ovarian cancer by immunochemistry.(A) The expression of CD90 in liver, spleen, lung, kidney and tumor in both groups. (B) Laser scanning confocal detected the expression of the red fluorescence in liver, spleen, lung, kidney and tumor in both groups.
Mentions: CD90 immunohistochemical results show that the CD90 mainly expressed in the tumor after the mice were injected with AFMSCs, and only a few AFMSCs were observed in the liver and spleen. The control group showed negative CD90 expression in the tumor and other tissues(Fig 7A) From the laser scanning confocal results we could see the red fluorescent labeled amniotic fluid mesenchymal stem cells in the experimental group with mainly gathered in the tumor site, and small number of stem cells appeared in the liver and spleen. The negative control group showed no red fluorescence(Fig 7B). The results might prompt that the AFMSCs had the tropism to ovarian cancer but not the normal tissue. The exhilarated discoveries also indicated the possibility of ovarian cancer cell-based targeted therapy.

Bottom Line: We successfully isolated the AFMSCs from thirteen of twenty amniotic fluid samples.RT-PCR results showed that the AFMSCs expressed stem cell marker OCT4.Meanwhile, the research emphasis in the future can also put in targeting therapy of ovarian cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Genecology and Obstetrics, Harbin Medical University, Harbin, Heilongjiang, China.

ABSTRACT
The mesenchymal stem cells (MSCs) derived from amniotic fluid (AF) have become an attractive stem cells source for cell-based therapy because they can be harvested at low cost and avoid ethical disputes. In human research, stem cells derived from AF gradually became a hot research direction for disease treatment, specifically for their plasticity, their reduced immunogenicity and their tumor tropism regardless of the tumor size, location and source. Our work aimed to obtain and characterize human amniotic fluid mesenchymal stem cells (AFMSCs) and detect their ovarian cancer tropsim in nude mice model. Ten milliliters of twenty independent amniotic fluid samples were collected from 16-20 week pregnant women who underwent amniocentesis for fetal genetic determination in routine prenatal diagnosis in the first affiliated hospital of Harbin medical university. We successfully isolated the AFMSCs from thirteen of twenty amniotic fluid samples. AFMSCs presented a fibroblastic-like morphology during the culture. Flow cytometry analyses showed that the cells were positive for specific stem cell markers CD73,CD90, CD105, CD166 and HLA-ABC (MHC class I), but negative for CD 45,CD40, CD34, CD14 and HLA-DR (MHC class II). RT-PCR results showed that the AFMSCs expressed stem cell marker OCT4. AFMSCs could differentiate into bone cells, fat cells and chondrocytes under certain conditions. AFMSCs had the high motility to migrate to ovarian cancer site but didn't have the tumorigenicity. This study enhances the possibility of AFMSCs as drug carrier in human cell-based therapy. Meanwhile, the research emphasis in the future can also put in targeting therapy of ovarian cancer.

No MeSH data available.


Related in: MedlinePlus